Your Questions, Answered
We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
The Eversense E3 CGM System uses a calibration algorithm that continuously assesses changes in the sensor’s glucose sensitivity. This sensitivity varies by individual, and from day to day. The need for 1 or 2 calibrations/day is determined by the system based on this continuous assessment, and there is no specific action a user can take to change the frequency of calibrations.
Download our discussion guide and bring it to your next appointment and talk to your doctor about how Eversense 365 may be a better fit for your diabetes management plan. We will work with you and your health care provider to manage your insurance claim.
Download our discussion guide and bring it to your next appointment and talk to your doctor about how Eversense may be a better fit for your diabetes management plan. We will work with you and your health care provider to manage your insurance claim.
Yes, insurance may cover both the product (sensor and transmitter) and the insertion and removal procedures. However every situation is different, so we recommend you get in touch via our pre-qualify form and an Eversense Expert can confirm what insurance covers for you and what out-of-pocket costs you may have.
Eversense® E3 is not indicated for use in children.
Eversense® E3 is a continuous glucose monitoring system indicated for the management of diabetes in adults age 18 years and older.
In extreme temperature, the system will present a High Sensor or High Transmitter Temperature Alert. Once the condition changes back to normal operating range, the system will display glucose values again.
Transmitter:
An alert appears every 20 minutes when your smart transmitter temperature is too high.
No glucose reading is displayed until the smart transmitter temperature is within normal operating conditions.
Reduce the smart transmitter temperature by moving to a cooler environment. Once the smart transmitter temperature is below 42 °C (108 °F), it will resume displaying glucose values.
You may temporarily remove the smart transmitter to cool it down. Once the smart transmitter is back to a lower temperature, be sure to replace it over the sensor.
Sensor:
The High Sensor Temperature Alert will appear every 20 minutes when the sensor temperature is too high. No glucose reading is displayed until the sensor temperature is within normal operating conditions. Go to a cooler environment to reduce the sensor temperature. Briefly remove the smart transmitter while the sensor temperature cools to between 26 - 40° C (81 - 104 °F). Then put the smart transmitter back on to start receiving glucose values again from the sensor. When you place the smart transmitter back on the sensor site, it may take up to 10 minutes for sensor communication to re-start and for glucose readings to appear in the app.
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
PP-SENS-E3-GBL-0060